552 related articles for article (PubMed ID: 27473417)
21. [Assessment of SUSARs. Clinical evaluation of single cases in terms of regulatory requirements].
Wroblewski H; Schmickler M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):459-63. PubMed ID: 15830258
[TBL] [Abstract][Full Text] [Related]
22. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
McKee AE; Markon AO; Chan-Tack KM; Lurie P
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
[TBL] [Abstract][Full Text] [Related]
23. Pharmacovigilance in Clinical Trials: Current Practice and Challenges.
Cheaib N
Account Res; 2016; 23(1):23-30. PubMed ID: 26528639
[TBL] [Abstract][Full Text] [Related]
24. [From molecule to medicine--drug development].
Bruhn C
Dtsch Med Wochenschr; 2010 Feb; 135(6):p5. PubMed ID: 20151355
[No Abstract] [Full Text] [Related]
25. [The role of the Danish Medical Products Agency in clinical trials].
Simonsen AC
Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
[TBL] [Abstract][Full Text] [Related]
26. Expedited safety reporting requirements for human drug and biological products; correction--FDA. Final rule; correction.
Fed Regist; 1998 Mar; 63(58):14611-2. PubMed ID: 10177754
[TBL] [Abstract][Full Text] [Related]
27. Narrative Review: The FDA's Perfunctory Approach of Dietary Supplement Regulations Giving Rise to Copious Reports of Adverse Events.
Li W; Wertheimer A
Innov Pharm; 2023; 14(1):. PubMed ID: 38035313
[No Abstract] [Full Text] [Related]
28. Adverse drug events and the Freedom of Information Act: an apple in Eden.
Stang PE; Fox JL
Ann Pharmacother; 1992 Feb; 26(2):238-43. PubMed ID: 1554939
[TBL] [Abstract][Full Text] [Related]
29. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world.
Echols RM
Ann N Y Acad Sci; 2011 Dec; 1241():153-61. PubMed ID: 22191531
[TBL] [Abstract][Full Text] [Related]
30. Expanded access to investigational drugs for treatment use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
[TBL] [Abstract][Full Text] [Related]
31. Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
Theoret MR; Pai-Scherf LH; Chuk MK; Prowell TM; Balasubramaniam S; Kim T; Kim G; Kluetz PG; Keegan P; Pazdur R
Clin Cancer Res; 2015 Oct; 21(20):4545-51. PubMed ID: 26473190
[TBL] [Abstract][Full Text] [Related]
32. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
[TBL] [Abstract][Full Text] [Related]
33. The Role of Adverse Event Reporting in the FDA Response to a Multistate Outbreak of Liver Disease Associated with a Dietary Supplement.
Klontz KC; DeBeck HJ; LeBlanc P; Mogen KM; Wolpert BJ; Sabo JL; Salter M; Seelman SL; Lance SE; Monahan C; Steigman DS; Gensheimer K
Public Health Rep; 2015; 130(5):526-32. PubMed ID: 26327730
[TBL] [Abstract][Full Text] [Related]
34. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
35. Investigational new drug, antibiotic, and biological product applications; clinical hold and termination--FDA. Final rule.
Fed Regist; 1992 Apr; 57(73):13244-9. PubMed ID: 10118458
[TBL] [Abstract][Full Text] [Related]
36. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
[TBL] [Abstract][Full Text] [Related]
37. Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors.
Mileham KF; Schenkel C; Chuk MK; Buchmeier A; Perez RP; Hurley P; Levit LA; Garrett-Mayer E; Davis C; Bruinooge SS; Vose J
J Oncol Pract; 2019 Dec; 15(12):e1050-e1065. PubMed ID: 31647695
[TBL] [Abstract][Full Text] [Related]
38. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
Noah BA; Brushwood DB
J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
[TBL] [Abstract][Full Text] [Related]
39. International Conference on Harmonisation; Electronic Transmission of Postmarket Individual Case Safety Reports for Drugs and Biologics, Excluding Vaccines; Availability of Food and Drug Administration Regional Implementation Specifications for ICH E2B(R3) Reporting to the Food and Drug Administration Adverse Event Reporting System. Notice of Availability.
Food and Drug Administration, HHS
Fed Regist; 2016 Jun; 81(121):40890-1. PubMed ID: 27373012
[TBL] [Abstract][Full Text] [Related]
40. Operation of a radiopharmacy for a clinical trial.
Norenberg JP; Petry NA; Schwarz S
Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
